HYPERIMAGE

Hybrid PET-MR system for concurrent ultra-sensitive imaging

 Coordinatore PHILIPS TECHNOLOGIE GMBH 

 Organization address address: LUEBECKERTORDAM 5
city: HAMBURG
postcode: 20099

contact info
Titolo: Mr.
Nome: Patrick
Cognome: Keur
Email: send email
Telefono: +31 402740361
Fax: +31 402745829

 Nazionalità Coordinatore Germany [DE]
 Sito del progetto http://www.iminds.be
 Totale costo 7˙333˙956 €
 EC contributo 4˙940˙000 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-04-01   -   2011-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    PHILIPS TECHNOLOGIE GMBH

 Organization address address: LUEBECKERTORDAM 5
city: HAMBURG
postcode: 20099

contact info
Titolo: Mr.
Nome: Patrick
Cognome: Keur
Email: send email
Telefono: +31 402740361
Fax: +31 402745829

DE (HAMBURG) coordinator 0.00
2    FONDAZIONE BRUNO KESSLER

 Organization address address: VIA SANTA CROCE 77
city: TRENTO
postcode: 38122

contact info
Titolo: Mr.
Nome: Umberto
Cognome: Silvestri
Email: send email
Telefono: +39 0461 314375
Fax: +39 0461 314588

IT (TRENTO) participant 0.00
3    FUNDACION CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III

 Organization address address: C/ MELCHOR FERNANDEZ ALMAGRO 3
city: MADRID
postcode: 28029

contact info
Titolo: Dr.
Nome: Julia
Cognome: Redondo
Email: send email
Telefono: +34 91 453 12 30
Fax: +34 91 453 12 45

ES (MADRID) participant 0.00
4    IMINDS VZW

 Organization address address: GASTON CROMMENLAAN 8/102
city: GENT
postcode: 9050

contact info
Titolo: Dr.
Nome: Steven
Cognome: Staelens
Email: send email
Telefono: +32 9 332 21 47
Fax: +32 9 332 41 59

BE (GENT) participant 0.00
5    KING'S COLLEGE LONDON

 Organization address address: Strand
city: LONDON
postcode: WC2R 2LS

contact info
Titolo: Mr.
Nome: Paul
Cognome: Labbett
Email: send email
Telefono: +44 20 7848 8184
Fax: +44 20 7848 8187

UK (LONDON) participant 0.00
6    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

 Organization address address: SEMINARSTRASSE 2
city: HEIDELBERG
postcode: 69117

contact info
Titolo: Dr.
Nome: Norbert
Cognome: Huber
Email: send email
Telefono: 496222000000
Fax: 496222000000

DE (HEIDELBERG) participant 0.00
7    STICHTING HET NEDERLANDS KANKER INSTITUUT

 Organization address address: PLESMANLAAN 121
city: AMSTERDAM
postcode: 1066 CX

contact info
Titolo: Dr.
Nome: Henri
Cognome: Van Luenen
Email: send email
Telefono: 31205122097
Fax: 31206691383

NL (AMSTERDAM) participant 0.00
8    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

 Organization address address: Martinistrasse 52
city: HAMBURG
postcode: 20246

contact info
Titolo: Mr.
Nome: Michael
Cognome: Kaul
Email: send email
Telefono: 4940430000000
Fax: 4940430000000

DE (HAMBURG) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

tomography    tissue    motion    time    monitoring    therapy    hybrid    imaging    limitations    tof    mr    artefacts    oncology    combination    lesion    soft    contrast    clinical    ct    detector    pet    compensation   

 Obiettivo del progetto (Objective)

'The HYPERImage project will develop a novel hybrid system for simultaneous whole-body PET/MR imaging for humans. It will advance the required Time-of-Flight (ToF) PET technology, and the software for MR mediated compensation of motion artefacts. The hybrid system will be validated in pre-clinical and initial clinical studies, for exemplary applications in cardiovascular diseases, and in breast cancer as one of the most relevant applications in oncology. For latter application, the concept will be extended from pure imaging towards image-guided therapy. Positron Emission Tomography (PET) is the most sensitive molecular imaging modality. Hybrid PET/CT systems using Computer Tomography (CT) to provide the anatomical reference for lesion localization have evolved to be the best choice for a number of applications in cardiology and oncology. However, PET/CT has drawbacks and limitations: CT is associated with radiation dose and lacks soft tissue contrast, and PET suffers from restrictions in small lesion detectability, both due to motion artefacts during the scan, and due to detector limitations. A hybrid combination of ToF-PET with a 3T MR has the potential to overcome these shortcomings, by fully exploiting the superior soft-tissue contrast of MR in combination with a new MR-compatible solid-state PET detector technology, and a sophisticated motion compensation enabled by concurrent acquisition of both MR and time-stamped PET data. In addition, the versatility of MR allows imaging of supplementary functional parameters like temperature, elasticity, and diffusion, enabling this new hybrid imaging concept to open up new fields of applications in therapy guidance and therapy response monitoring. The consortium consists of one large company, one SME, three academic partners and two research institutes from five different EU countries. It combines leadership in technology with pioneer experience in using biomedical imaging for diagnosis and therapy monitoring.'

Altri progetti dello stesso programma (FP7-HEALTH)

IFNACTION (2009)

A system view on the differential activities of human type I interferons

Read More  

LSE (2013)

LSE TECHNOLOGY APPROACH TO GENERATE INNOVATIVE KINASE INHIBITOR DRUGS

Read More  

HERMIONE-2MAN (2013)

First in Man Novel Anticancer Therapeutic based on Dependence Receptors Concept

Read More